<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Leuk Res</journal-id>
      <journal-id journal-id-type="iso-abbrev">Leuk. Res</journal-id>
      <journal-title-group>
        <journal-title>Leukemia Research</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0145-2126</issn>
      <issn pub-type="epub">1873-5835</issn>
      <publisher>
        <publisher-name>Pergamon Press</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">22578776</article-id>
      <article-id pub-id-type="pmc">3389344</article-id>
      <article-id pub-id-type="publisher-id">S0145-2126(12)00190-7</article-id>
      <article-id pub-id-type="doi">10.1016/j.leukres.2012.04.015</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Brief Communication</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title><italic>PAX5-AUTS2</italic>: A recurrent fusion gene in childhood B-cell precursor acute lymphoblastic leukemia</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Denk</surname>
            <given-names>Dagmar</given-names>
          </name>
          <xref rid="aff0005" ref-type="aff">a</xref>
          <xref rid="fn0005" ref-type="fn">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nebral</surname>
            <given-names>Karin</given-names>
          </name>
          <xref rid="aff0005" ref-type="aff">a</xref>
          <xref rid="fn0005" ref-type="fn">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bradtke</surname>
            <given-names>Jutta</given-names>
          </name>
          <xref rid="aff0010" ref-type="aff">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pass</surname>
            <given-names>Gertrud</given-names>
          </name>
          <xref rid="aff0015" ref-type="aff">c</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>M&#xF6;ricke</surname>
            <given-names>Anja</given-names>
          </name>
          <xref rid="aff0020" ref-type="aff">d</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Attarbaschi</surname>
            <given-names>Andishe</given-names>
          </name>
          <xref rid="aff0025" ref-type="aff">e</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Strehl</surname>
            <given-names>Sabine</given-names>
          </name>
          <email>sabine.strehl@ccri.at</email>
          <xref rid="aff0005" ref-type="aff">a</xref>
          <xref rid="cor0005" ref-type="corresp">&#x204E;</xref>
        </contrib>
      </contrib-group>
      <aff id="aff0005"><label>a</label>CCRI, Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria</aff>
      <aff id="aff0010"><label>b</label>Onkogenetisches Labor der Universit&#xE4;ts-Kinderklinik Gie&#xDF;en, Gie&#xDF;en, Germany</aff>
      <aff id="aff0015"><label>c</label>Labdia Labordiagnostik, St. Anna Kinderkrebsforschung, Vienna, Austria</aff>
      <aff id="aff0020"><label>d</label>Department of Pediatrics, Children's University Hospital, University Hospital Schleswig-Holstein, Campus Kiel, Germany</aff>
      <aff id="aff0025"><label>e</label>Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital and Department of Pediatrics, Medical University of Vienna, Vienna, Austria</aff>
      <author-notes>
        <corresp id="cor0005"><label>&#x204E;</label>Corresponding author. Tel.: +43 1 40470 4020; fax: +43 1 40470 7150. <email>sabine.strehl@ccri.at</email></corresp>
        <fn id="fn0005">
          <label>1</label>
          <p>These authors contributed equally to this manuscript.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="pmc-release">
        <day>1</day>
        <month>8</month>
        <year>2012</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="ppub">.-->
      <pub-date pub-type="ppub">
        <month>8</month>
        <year>2012</year>
      </pub-date>
      <volume>36</volume>
      <issue>8</issue>
      <fpage>e178</fpage>
      <lpage>e181</lpage>
      <history>
        <date date-type="received">
          <day>15</day>
          <month>3</month>
          <year>2012</year>
        </date>
        <date date-type="rev-recd">
          <day>15</day>
          <month>3</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>16</day>
          <month>4</month>
          <year>2012</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2012 Elsevier Ltd.</copyright-statement>
        <copyright-year>2012</copyright-year>
        <copyright-holder>Elsevier Ltd</copyright-holder>
        <license xlink:href="https://creativecommons.org/licenses/by-nc-nd/3.0/">
          <license-p>Open Access under <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/3.0/">CC BY-NC-ND 3.0</ext-link> license</license-p>
        </license>
      </permissions>
      <abstract>
        <p><italic>PAX5</italic> rearrangements resulting in the expression of fusion transcripts account for 2&#x2013;3% of childhood B-cell precursor acute lymphoblastic leukemia. Most <italic>PAX5</italic> fusions are rare and many of them have only been described in a couple of, or even only in single, cases. We have identified the third case with a <italic>PAX5-AUTS2</italic> fusion, which results from unbalanced t(7;9)(q11.2;p13.2) rearrangements. Our findings substantiate that <italic>PAX5-AUTS2</italic> is a recurrent fusion gene in pediatric B-cell precursor acute lymphoblastic leukemia, and we summarize the clinical characteristics of such patients.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>
          <italic>PAX5-AUTS2</italic>
        </kwd>
        <kwd>Fusion transcript</kwd>
        <kwd>Childhood acute lymphoblastic leukemia</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="sec0005">
      <label>1</label>
      <title>Introduction</title>
      <p>In pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) <italic>PAX5</italic> is one of the most frequent targets affected by genetic alterations including deletions, point mutations, and gene rearrangements <xref rid="bib0005" ref-type="bibr">[1]</xref>. <italic>PAX5</italic> deletions and <italic>PAX5</italic> mutations are found in about 30% and 5&#x2013;7% of the cases, respectively, and <italic>PAX5</italic> rearrangements in 2&#x2013;3% <xref rid="bib0005 bib0010 bib0015 bib0020" ref-type="bibr">[1&#x2013;4]</xref>. <italic>PAX5</italic> rearrangements either result in <italic>bona fide</italic> in-frame fusions and the expression of chimeric transcripts <xref rid="bib0005 bib0015 bib0020" ref-type="bibr">[1,3,4]</xref> or in <italic>PAX5</italic> fusions to genes in opposite orientation, out-of-frame fusions or the expression of truncated isoforms <xref rid="bib0020" ref-type="bibr">[4]</xref>.</p>
      <p>To date, 16 different in-frame PAX5 fusion partners comprising a heterogeneous group of genes that encode transcription factors, structural proteins, the non-receptor tyrosine kinase JAK2, and several with so far unknown functions have been reported <xref rid="bib0005 bib0015 bib0020" ref-type="bibr">[1,3,4]</xref>. A unifying feature of all PAX5 fusion proteins is the retention of the PAX5 paired DNA-binding domain (PD), which is fused to either the entire fusion partner protein or its C-terminal portion <xref rid="bib0005 bib0015 bib0020" ref-type="bibr">[1,3,4]</xref>.</p>
      <p>While many of the <italic>PAX5</italic> fusions have so far only been observed in a couple of, or only single, cases, a number of them are more commonly found. The most frequently observed rearrangements are <italic>PAX5-ETV6</italic> and <italic>PAX5-C20orf112</italic> followed by <italic>PAX5-ELN</italic>, <italic>PAX5-FOXP1</italic>, and <italic>PAX5-JAK2</italic> each of which has been detected in at least three cases <xref rid="bib0005 bib0015 bib0020 bib0025" ref-type="bibr">[1,3&#x2013;5]</xref>.</p>
      <p>We here report the third case with a <italic>PAX5-AUTS2</italic> fusion resulting from unbalanced t(7;9)(q11.2;p13.2) rearrangements and summarize the clinical and laboratory characteristics of these patients.</p>
    </sec>
    <sec sec-type="materials-methods" id="sec0010">
      <label>2</label>
      <title>Patient and methods</title>
      <sec id="sec0015">
        <label>2.1</label>
        <title>Case report</title>
        <p>A 7-month-old boy presented with 158&#xA0;&#xD7;&#xA0;10<sup>9</sup>/L leucocytes in the peripheral blood (PB) and 91% and 89% blast cell infiltration in the PB and bone marrow (BM), respectively (<xref rid="tbl0005" ref-type="table">Table 1</xref>). The blast cells showed an L1 morphology and immunophenotyping established the diagnosis of a CD10<sup>+</sup> BCP-ALL. Ninety percent of the blast cells were CD19 and CD10 positive and &#x223C;10% weakly positive for cytoplasmic IgM; and they were negative for the myeloid markers CD13, CD15, CD33, and MPO and the T-cell markers cytoplasmic CD3 and surface CD7.</p>
        <p>Because of a poor prednisone response at day 8 the patient was treated, with informed consent, in the high risk group (HRG) of the ALL-BFM 90 clinical trial. A complete morphologic remission (CR) was achieved after completion of induction therapy; however, 2.1 years after initial diagnosis the patient had a central nervous system (CNS) relapse. The patient achieved a second CR but died of an infectious complication 3.4 years after initial diagnosis. Cytogenetics of the PB showed a 46,XY,t(7;9)(q11;p13) karyotype, and fluorescence in situ hybridization (FISH) indicated a <italic>PAX5</italic> rearrangement. The patient's laboratory and clinical parameters are summarized in <xref rid="tbl0005 tbl0010" ref-type="table">Tables 1 and 2</xref>.</p>
      </sec>
      <sec id="sec0020">
        <label>2.2</label>
        <title>FISH and Reverse Transcription-Polymerase Chain Reaction</title>
        <p>FISH using <italic>PAX5</italic>-specific cosmid probes was conducted as described <xref rid="bib0015" ref-type="bibr">[3]</xref>. RT-PCR for the detection of <italic>PAX5</italic>-<italic>AUTS2</italic> transcripts was performed using primers PAX5ex5-F1 (5&#x2032;-TACTCCATCAGCGGCATCC-3&#x2032;) and AUTS2ex8-R1 (5&#x2032;-TATTGGCTGTGCGACCTGAG-3&#x2032;) located in exons 5 and 8 of <italic>PAX5</italic> and <italic>AUTS2</italic>, respectively; the amplification product was directly sequenced (Eurofins, MWG, Operon, Germany). The exon nomenclature used corresponds to that of the NCBI reference sequences <italic>PAX5</italic> NM_016734.1 and <italic>AUTS2</italic> NM_015570.2 (accessed March 2012).</p>
      </sec>
      <sec id="sec0025">
        <label>2.3</label>
        <title><italic>In silico</italic> protein analysis</title>
        <p>Protein analysis was performed using BLASTP and COBALT (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/">http://www.ncbi.nlm.nih.gov</ext-link>), PSORTII (<ext-link ext-link-type="uri" xlink:href="http://psort.hgc.jp/">http://psort.hgc.jp</ext-link>) and CAST (<ext-link ext-link-type="uri" xlink:href="http://athina.biol.uoa.gr/CAST/">http://athina.biol.uoa.gr/CAST/</ext-link>). Further information regarding the AUTS2 protein family and posttranslational modifications were obtained from PRINTS (<ext-link ext-link-type="uri" xlink:href="http://www.bioinf.man.ac.uk/">http://www.bioinf.man.ac.uk/</ext-link>) and the PhosphoSitePlus<sup>&#xAE;</sup> database (<ext-link ext-link-type="uri" xlink:href="http://www.phosphosite.org/">http://www.phosphosite.org</ext-link>).</p>
      </sec>
    </sec>
    <sec id="sec0030">
      <label>3</label>
      <title>Results and discussion</title>
      <p>Interphase FISH of a pediatric BCP-ALL with a t(7;9)(q11;p13) using <italic>PAX5</italic>-specific probes detected a 3&#x2032;-end deletion of the gene (<xref rid="fig0005" ref-type="fig">Fig. 1</xref>A) suggesting the presence of a <italic>PAX5</italic> fusion with a partner gene located at 7q11. Subsequent RT-PCR revealed the expression of <italic>PAX5-AUTS2</italic> transcripts, in which exon 6 of <italic>PAX5</italic> was fused to exon 6 of <italic>AUTS2</italic> (<xref rid="fig0005" ref-type="fig">Fig. 1</xref>B and C). Similar in-frame fusions of <italic>PAX5</italic> exon 6 to <italic>AUTS2</italic> exons 4 or 7 have been previously described <xref rid="bib0030 bib0035" ref-type="bibr">[6,7]</xref>. Therefore, the breakpoints within <italic>AUTS2</italic> appear to be variable but that within <italic>PAX5</italic> consistently occurs in intron 6.</p>
      <p>Since <italic>PAX5</italic> and <italic>AUTS2</italic> are transcribed in the same &#x2013; centromere to telomere &#x2013; orientation, a reciprocal translocation may generate the fusion gene. However, in two cases due to loss of the der(7) chromosome the translocation was unbalanced (<xref rid="tbl0005" ref-type="table">Table 1</xref>). This is also reflected by the detection of one of the cases by SNP arrays (No. 1; <xref rid="tbl0005" ref-type="table">Table 1</xref>), which can only indicate fusion genes in case of unbalanced rearrangements <xref rid="bib0030" ref-type="bibr">[6]</xref>. Karyotyping of this previously published case now confirmed loss of the der(7). The cytogenetically unbalanced translocations in two of the <italic>PAX5-AUTS2</italic> cases and loss of the <italic>PAX5</italic> 3&#x2032;-end in the third one underline the observation that in the majority of <italic>PAX5</italic>-rearranged cases the reciprocal fusion transcripts are not expressed <xref rid="bib0015 bib0020" ref-type="bibr">[3,4]</xref> and that, thus, the <italic>PAX5</italic>-partner fusions drive leukemogenesis <xref rid="bib0005" ref-type="bibr">[1]</xref>.</p>
      <p>The putative consensus chimeric protein deduced from the fusion transcripts not only contains the PAX5 PD, which is typically retained in all PAX5 fusion proteins <xref rid="bib0005 bib0015 bib0020" ref-type="bibr">[1,3,4]</xref>, but also the octapeptide motif, the nuclear localization signal (NLS), and the homeodomain, which are fused to the C-terminal regions of AUTS2 (<xref rid="fig0005" ref-type="fig">Fig. 1</xref>D). With the exception of PAX5-ETV6, in which only the PAX5 PD is maintained, in several PAX5 fusions the breakpoint occurs in intron 5, therefore, also the NLS is present <xref rid="bib0005 bib0020" ref-type="bibr">[1,4]</xref>. In the remaining PAX5 fusions the breakpoints are located within further downstream introns resulting in the retention of additional conserved protein domains <xref rid="bib0005 bib0020" ref-type="bibr">[1,4]</xref>. Thus, PAX5-AUTS2 may belong to a subtype of PAX5 fusion proteins whose function might be distinct from those that retain only the PD.</p>
      <p><italic>AUTS2</italic>, which is expressed in the developing brain, has been described as autism susceptibility candidate gene 2 and its mutation has also been linked to autosomal dominant mental retardation <xref rid="bib0040" ref-type="bibr">[8]</xref>. The nuclear protein AUTS2 belongs to the fibrosin-1-like protein family, which consists of AUTS2, FBRS (fibrosin), and FBRSL1 (fibrosin-like 1), which share a so-called FIBROSIN1LPF 5-element fingerprint signature. Moreover, AUTS2 is highly conserved among species and harbors several putative NLSs, two proline- alternating with two histidine-rich regions, and two potential serine phosphorylation sites (<xref rid="fig0005" ref-type="fig">Fig. 1</xref>D); the function of the latter sites has, however, not been analyzed in detail yet. In the putative PAX5-AUTS2 chimeric protein almost the entire AUTS2 protein, except for the region containing the NLSs, is fused to PAX5 which retains its NLS (<xref rid="fig0005" ref-type="fig">Fig. 1</xref>D).</p>
      <p>Regarding the clinical course, all three <italic>PAX5-AUTS2</italic> positive patients were assigned to different risk arms of the respective clinical trials. They all achieved a CR after completion of induction therapy; however, two of the patients experienced an early relapse and both patients died, one from an infectious complication in second CR and one from progressive leukemia after a further relapse. The third patient remains in first CR for more than two years after diagnosis (<xref rid="tbl0010" ref-type="table">Table 2</xref>).</p>
      <p>The general rarity of recurrent <italic>PAX5</italic> fusion gene positive BCP-ALL precludes any conclusions regarding their prognostic value. Yet, although the number of patients is very small, it is interesting to note that two of the three <italic>PAX5-AUTS2</italic> patients had a CNS involvement either at the time of diagnosis or relapse and two patients experienced early relapses tentatively indicating that <italic>PAX5-AUTS2</italic> positive cases may have a rather poor outcome.</p>
      <p>In summary, the description of now three cases with a <italic>PAX5-AUTS2</italic> fusion confirms its recurrence in pediatric BCP-ALL and emphasizes the importance of functional studies of <italic>PAX5</italic> fusion genes to understand the pathogenesis of this rare disease.</p>
    </sec>
    <sec id="sec0035">
      <title>Conflict of interest</title>
      <p>All authors declare no conflicts of interest.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="bib0005">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Medvedovic</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Ebert</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Tagoh</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Busslinger</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Pax5: a master regulator of B cell development and leukemogenesis</article-title>
          <source>Adv Immunol</source>
          <volume>111</volume>
          <year>2011</year>
          <fpage>179</fpage>
          <lpage>206</lpage>
          <pub-id pub-id-type="pmid">21970955</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0010">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Familiades</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Bousquet</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Lafage-Pochitaloff</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Bene</surname>
              <given-names>M.C.</given-names>
            </name>
            <name>
              <surname>Beldjord</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>De Vos</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study</article-title>
          <source>Leukemia</source>
          <volume>23</volume>
          <issue>11</issue>
          <year>2009</year>
          <fpage>1989</fpage>
          <lpage>1998</lpage>
          <pub-id pub-id-type="pmid">19587702</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0015">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nebral</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Denk</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Attarbaschi</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Konig</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Mann</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Haas</surname>
              <given-names>O.A.</given-names>
            </name>
          </person-group>
          <article-title>Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia</article-title>
          <source>Leukemia</source>
          <volume>23</volume>
          <issue>1</issue>
          <year>2009</year>
          <fpage>134</fpage>
          <lpage>143</lpage>
          <pub-id pub-id-type="pmid">19020546</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0020">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Coyaud</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Struski</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Prade</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Familiades</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Eichner</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Quelen</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Wide diversity of PAX5 alterations in B-ALL: a Groupe Francophone de Cytogenetique Hematologique study</article-title>
          <source>Blood</source>
          <volume>115</volume>
          <issue>15</issue>
          <year>2010</year>
          <fpage>3089</fpage>
          <lpage>3097</lpage>
          <pub-id pub-id-type="pmid">20160164</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0025">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pichler</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Moricke</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Mann</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Teigler-Schlegel</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Niggli</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Nebral</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Prognostic relevance of dic(9;20)(p11;q13) in childhood B-cell precursor acute lymphoblastic leukaemia treated with Berlin&#x2013;Frankfurt&#x2013;Munster (BFM) protocols containing an intensive induction and post-induction consolidation therapy</article-title>
          <source>Br J Haematol</source>
          <volume>149</volume>
          <issue>1</issue>
          <year>2010</year>
          <fpage>93</fpage>
          <lpage>100</lpage>
          <pub-id pub-id-type="pmid">20067563</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0030">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kawamata</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Ogawa</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Zimmermann</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Niebuhr</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Stocking</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Sanada</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Cloning of genes involved in chromosomal translocations by high-resolution single nucleotide polymorphism genomic microarray</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <volume>105</volume>
          <issue>33</issue>
          <year>2008</year>
          <fpage>11921</fpage>
          <lpage>11926</lpage>
          <pub-id pub-id-type="pmid">18697940</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0035">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Coyaud</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Struski</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Dastugue</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Brousset</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Broccardo</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Bradtke</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>PAX5-AUTS2 fusion resulting from t(7;9)(q11.2;p13.2) can now be classified as recurrent in B cell acute lymphoblastic leukemia</article-title>
          <source>Leukemia Res</source>
          <volume>34</volume>
          <issue>12</issue>
          <year>2010</year>
          <fpage>e323</fpage>
          <lpage>e325</lpage>
          <pub-id pub-id-type="pmid">20723977</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0040">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bedogni</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Hodge</surname>
              <given-names>R.D.</given-names>
            </name>
            <name>
              <surname>Nelson</surname>
              <given-names>B.R.</given-names>
            </name>
            <name>
              <surname>Frederick</surname>
              <given-names>E.A.</given-names>
            </name>
            <name>
              <surname>Shiba</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Daza</surname>
              <given-names>R.A.</given-names>
            </name>
          </person-group>
          <article-title>Autism susceptibility candidate 2 (Auts2) encodes a nuclear protein expressed in developing brain regions implicated in autism neuropathology</article-title>
          <source>Gene Expr Patterns</source>
          <volume>10</volume>
          <issue>1</issue>
          <year>2010</year>
          <fpage>9</fpage>
          <lpage>15</lpage>
          <pub-id pub-id-type="pmid">19948250</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <ack>
      <title>Acknowledgments</title>
      <p>This work was supported by a grant from the <funding-source>Austrian Science Fund</funding-source> (FWF P21554-B19 to S.S.) and the <funding-source>St. Anna Kinderkrebsforschung</funding-source>.</p>
      <p><italic>Authors&#x2019; contributions</italic>: DD and KN conducted experiments and analyzed data; JB and GP performed cytogenetic analysis; AM and AA are responsible for the clinical data; SS supervised the study and drafted the manuscript. All authors approved the final manuscript.</p>
    </ack>
  </back>
  <floats-group>
    <fig id="fig0005">
      <label>Fig. 1</label>
      <caption>
        <p>Molecular genetic analysis of <italic>PAX5-AUTS2</italic> positive case. (A) FISH using <italic>PAX5</italic>-specific cosmids showing a 3&#x2032;-end deletion: 5&#x2032;-end-specific clone (green signals); 3&#x2032;-end-specific clone (red signals). (B) RT-PCR using primers located in <italic>PAX5</italic> exon 5 and <italic>AUTS2</italic> exon 8 resulting in amplification of <italic>PAX5-AUTS2</italic> fusion transcripts. M, molecular weight marker 100&#xA0;bp ladder (Promega); lane 1, patient No. 3; lane 2, normal control; lane 3, no template control. (C) Sequence chromatogram of the <italic>PAX5</italic>-<italic>AUTS2</italic> fusion junction showing fusion between exon 6 of <italic>PAX5</italic> and exon 6 of <italic>AUTS2</italic>. (D) Schematic representation of the structure of PAX5 (top) and AUTS2 (bottom) wild-type proteins as well as the putative consensus chimeric protein (middle). PD, paired domain; OP, octapeptide; HD, homeodomain; TA, transactivation domain; I, inhibitory domain; H, histidine-rich regions; P, proline-rich region; arrows indicate nuclear localization signal (NLS); filled lollipops represent serine phosphorylation sites.</p>
      </caption>
      <graphic xlink:href="gr1"/>
    </fig>
    <table-wrap id="tbl0005" position="float">
      <label>Table 1</label>
      <caption>
        <p>Patient and laboratory data of <italic>PAX5-AUTS2</italic> positive cases.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left">No.</th>
            <th align="left">Age (yrs)</th>
            <th align="left">Sex</th>
            <th align="left">WBC (&#xD7;10<sup>9</sup>/L)</th>
            <th align="left">Blasts BM</th>
            <th align="left">Morphology/phenotype</th>
            <th align="left">Karyotype</th>
            <th align="left">Reference</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="char">1</td>
            <td align="char">3.1</td>
            <td align="left">M</td>
            <td align="char">171.5</td>
            <td align="char">93%</td>
            <td align="left">L1/B-III</td>
            <td align="left">45,XY,-7,der(9)t(7;9)(q11;p13)[15]/46,XY[1]</td>
            <td align="left">Kawamata et al.<xref rid="tblfn0005" ref-type="table-fn">a</xref><xref rid="bib0030" ref-type="bibr">[6]</xref></td>
          </tr>
          <tr>
            <td align="char">2</td>
            <td align="char">2.8</td>
            <td align="left">F</td>
            <td align="char">5.6</td>
            <td align="char">80%</td>
            <td align="left">L1/B-III</td>
            <td align="left">45,XX,-7,der(9)t(7;9)(q11;p13),dup(16)(p11p13)[14]/<break/>46,XX[2]</td>
            <td align="left">Coyaud et al. <xref rid="bib0035" ref-type="bibr">[7]</xref></td>
          </tr>
          <tr>
            <td align="char">3</td>
            <td align="char">0.6</td>
            <td align="left">M</td>
            <td align="char">158.0</td>
            <td align="char">89%</td>
            <td align="left">L1/B-II/III</td>
            <td align="left">46,XY,t(7;9)(q11;p13)[8]</td>
            <td align="left">This work</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p>BM, bone marrow; WBC, white blood cell count; yrs, years.</p>
        </fn>
      </table-wrap-foot>
      <table-wrap-foot>
        <fn id="tblfn0005">
          <label>a</label>
          <p>Initially in this case no cytogenetic analysis was performed.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="tbl0010" position="float">
      <label>Table 2</label>
      <caption>
        <p>Clinical characteristics and outcome of <italic>PAX5-AUTS2</italic> positive cases.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left">No.</th>
            <th align="left">Clinical trial</th>
            <th align="left">CNS disease</th>
            <th align="left">MRD day 33</th>
            <th align="left">MRD day 78</th>
            <th align="left">MRD risk</th>
            <th align="left">Prednisone response</th>
            <th align="left">CR day 33</th>
            <th align="left">Risk group</th>
            <th align="left">Relapse</th>
            <th align="left">Time to relapse (yrs)<xref rid="tblfn0010" ref-type="table-fn">a</xref></th>
            <th align="left">Outcome</th>
            <th align="left">Follow-up (yrs)<xref rid="tblfn0015" ref-type="table-fn">b</xref></th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left">1</td>
            <td align="left">ALL-BFM 2000</td>
            <td align="left">Yes</td>
            <td align="left">10<sup>&#x2212;4</sup></td>
            <td align="left">Neg</td>
            <td align="left">IR</td>
            <td align="left">Good</td>
            <td align="left">Yes</td>
            <td align="left">MRG</td>
            <td align="left">1st BM<break/>2nd BM</td>
            <td align="left">1.4<break/>1.6</td>
            <td align="left">Dead</td>
            <td align="left">1.7</td>
          </tr>
          <tr>
            <td align="left">2</td>
            <td align="left">ALL-BFM 2000</td>
            <td align="left">No</td>
            <td align="left">Neg</td>
            <td align="left">Neg</td>
            <td align="left">LR</td>
            <td align="left">Good</td>
            <td align="left">Yes</td>
            <td align="left">SRG</td>
            <td align="left">/</td>
            <td align="left">/</td>
            <td align="left">1st CR</td>
            <td align="left">2.2+</td>
          </tr>
          <tr>
            <td align="left">3</td>
            <td align="left">ALL-BFM 90<xref rid="tblfn0020" ref-type="table-fn">c</xref></td>
            <td align="left">No</td>
            <td align="left">ND</td>
            <td align="left">ND</td>
            <td align="left">ND</td>
            <td align="left">Poor</td>
            <td align="left">Yes</td>
            <td align="left">HRG</td>
            <td align="left">CNS</td>
            <td align="left">2.1</td>
            <td align="left">Dead</td>
            <td align="left">3.4</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p>BM, bone marrow; CNS, central nervous system; CR, complete morphologic remission; MRD, minimal residual disease; ND, not determined; IR, intermediate risk; LR, low risk; MRG, medium risk group; SRG, standard risk group; HRG, high risk group; yrs, years.</p>
        </fn>
      </table-wrap-foot>
      <table-wrap-foot>
        <fn id="tblfn0010">
          <label>a</label>
          <p>From initial diagnosis.</p>
        </fn>
      </table-wrap-foot>
      <table-wrap-foot>
        <fn id="tblfn0015">
          <label>b</label>
          <p>Follow-up from initial diagnosis to date of death or last follow-up date.</p>
        </fn>
      </table-wrap-foot>
      <table-wrap-foot>
        <fn id="tblfn0020">
          <label>c</label>
          <p>In the ALL-BFM 90 trial MRD was not used as parameter for risk stratification.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>
</pmc-articleset>
